Use of antipsychotic medications in Australia between July 1995 and December 2001

Australian and New Zealand Journal of Psychiatry

Volumn 37, Issue 1, 2003, Pages 55-61

  Mond, Jonathan ^a   Morice, Rodney ^b   Owen, Cathy ^a   Korten, Ailsa ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CANBERRA HOSPITAL   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Atypical antipsychotic; Defined daily dose; Drug utilization

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEURALACTIL; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; QUETIAPINE; RISPERIDAL; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL DECANOATE;

ARTICLE; BODY WEIGHT DISORDER; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG UTILIZATION; HEALTH INSURANCE; HUMAN; HYPERPROLACTINEMIA; PHARMACY; POPULATION RESEARCH; PRESCRIPTION; PSYCHOSIS;

ANTIPSYCHOTIC AGENTS; AUSTRALIA; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; HUMANS; PRIMARY HEALTH CARE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES;

EID: 0346665571     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2003.01110.x     Document Type: Article

References (42)

1. Murray RR, Schooler NR (chairs). Novel antipsychotic use in schizophrenia (academic highlights). Journal of Clinical Psychiatry 2000; 61:223-232.
2. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. Journal of Clinical Psychiatry 1999; 60 (Suppl. 3):3-7.
3. Keks N, Mazumdar P, Steele K. The new antipsychotics: how much better are they? Australian Family Physician 2000; 29:445-450.
4. Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45:789-796.
5. Sharif ZA, Raza A, Ratakonda SS. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. Journal of Clinical Psychiatry 2000; 61:498-504.
6. The Expert Consensus Guideline Series. Treatment of schizophrenia. Journal of Clinical Psychiatry 1999; 60 (Suppl. 11): 1-80.
7. Geddes J. Prevention of relapse in schizophrenia. New England Journal of Medicine 2002; 346:56-58.
8. Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. European Psychiatry 2000; 15:220-226.
9. Galletly C. Prescribing of psychotropic drugs in an acute inpatient unit. Australian and New Zealand Journal of Psychiatry 1999; 33:281-282.
10. Lambert T. Pharmacology of depot antipsychotics. In: Directions in psychiatry. Forum 6. Sydney: Eli Lilly, 1999; 16-17.
11. Keks NA, Altson K, Hope J et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Australian and New Zealand Journal of Psychiatry 1999; 33:896-901.
12. Lambert T, Singh B. Psychotropic prescribing in community mental health clinics. International Journal of Neuropsychopharmacology, 22nd CINP Brussels, 2000; 3:S123.
13. Jablensky A, McGrath J, Herrman H et al. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Australian and New Zealand Journal of Psychiatry 2000; 34:221-236.
14. World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2nd edn. Oslo: WHO, 1998.
15. Mant A, Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D. Benzodiazepine utilization in Australia: report from a new pharmacoepidemiological database. Australian Journal of Public Health 1993; 17:345-349.
16. Commonwealth Department of Health and Aged Care. Australian statistics on medicines, 1998. Canberra: Department of Health and Aged Care, 1999.
17. McManus P, Primrose JG, Henry DA, Birkett DJ, Lindner J, Day RO. Pattern of non-steroidal anti-inflammatory drug use in Australia: a report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Medical Journal of Australia 1996; 164:589-592.
18. McManus P, Hammond ML, Whicker SD, Primrose JG, Mant A, Fairall SR. Antibiotic use in the Australian community. Medical Journal of Australia 1997; 167:124-127.
19. McManus P, Mant A, Mitchell PB, Montgomery WS, Marley J, Auland ME. Recent trends in the use of antidepressant drugs in Australia. Medical Journal of Australia 2000; 173:458-461.
20. Commonwealth Department of Health and Aged Care. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners, May 2001. Canberra: Department of Health and Aged Care, 2001.
21. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs, 2001. Oslo: WHO, 2000.
22. Australian Bureau of Statistics. Australian Demographic Statistics. Cat, 3101.0. (1995-2001). Canberra: ABS, 2001.
23. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. Journal of Clinical Psychiatry 1997; 58 (Suppl. 10):63-72.
24. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. Journal of Psychiatric Research 2001; 35:187-191.
25. Parker G, Malhi G. Are atypical antipsychotic drugs also atypical antidepressants? Australian and New Zealand Journal of Psychiatry 2001; 35:631-638.
26. Snowdon J. A follow-up survey of psychotropic drug use in Sydney nursing homes. Medical Journal of Australia 1999; 170:299-301.
27. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. European Archives of Psychiatry and Clinical Neuroscience 2000; 250:274-285.
28. Shen WW. The need for depot atypical antipsychotics in the US. Psychiatric Services 1998; 49:727.
29. Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 2001; 179:290-299.
30. Novartis Pharmaceuticals. Melleril (thioridazine) - important changes to product information. New Jersey: Novartis, September 2000.
31. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997; 17:407-418.
32. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2001; 158:765-774.
33. Thomas CS, Lewis S. Which atypical antipsychotic? British Journal of Psychiatry 1998; 172:106-109.
34. Stahl SM. Selecting an atypical antipsychotic by combining clinical experiences with guidelines from clinical trials. Journal of Clinical Psychiatry 1999; 60 (Suppl. 10):31-41.
35. Ganguli R. Weight gain associated with antipsychotic drugs. Journal of Clinical Psychiatry 1999; 60 (Suppl. 21):20-24.
36. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156:1686-1696.
37. Goldstein LE, Sporn J, Brown S et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40:438-443.
38. Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. Journal of Clinical Psychiatry 2001; 62:749-756.
39. Therapeutic Guidelines. Psychotropic drug guidelines, 4th edn. Melbourne: Therapeutic Guidelines, 2000.
40. Carpenter WT, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. American Journal of Psychiatry 1999; 156:412-418.
41. Kendrick T. The newer, 'atypical' antipsychotic drugs - their development and current therapeutic use. British Journal of General Practice 1999; 49:745-749.
42. Keks N, Burrows GD. Psychotropic drug prescribing: first the good news. Medical Journal of Australia 1999; 170:293-294.